1. Home
  2. Clinical Topics
  3. FDA approves new treatment for eosinophilic granulomatosis with polyangiitis
Clinical TopicsDrugs and DevicesWeb Exclusives
fda treatment eosinophilic granulomatosis polyangiitis autoimmune disease vasculitis therapy approve stamp

FDA approves new treatment for eosinophilic granulomatosis with polyangiitis

Share

On Dec. 12, the U.S. Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis. This new indication if the first FDA-approved therapy for EGPA.

Read more via Fda.gov.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts